iCamuno Biotherapeutics on Muck Rack

iCamuno Biotherapeutics

As seen in: Frontiers, PR Newswire Asia
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with iCamuno

Contact iCamuno, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Stem Cell Therapy developers I Peace and iCamuno Biotherapeutics Start Natural Killer Cell Trial for Ovarian Cancer

|
By I Peace, iCamuno Biotherapeutics
| PR Newswire Asia
, /PRNewswire/ -- I Peace, a pioneering CDMO in induced pluripotent stem (iPS) cells, and iCamuno Biotherapeutics, a biotech company developing iPS cell-based therapies, today announced a significant milestone with the dosing of the first patient in a clinical trial using iPS cell-derived natural killer (iNK) cells for ovarian cancer immunotherapy.
Open in Who Shared Issue with article?

The Haematopoietically-expressed homeobox transcription factor: roles in development, physiology and disease

|
By iCamuno Biotherapeutics, Stephen Daley, Brian Laidlaw, Arístides López-Márquez
| Frontiers
Jacob T. Jackson1*, Stephen L. Nutt1,2 and Matthew P.
Open in Who Shared Issue with article?

The Haematopoietically-expressed Homeobox (Hhex) transcription factor: roles in development, physiology and disease

|
By iCamuno Biotherapeutics
| Frontiers
Jacob T. Jackson1*, Stephen L. Nutt1, 2 and Matthew P.
Open in Who Shared Issue with article?
See all 3 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified